Featured Research

from universities, journals, and other organizations

Avastin Effective At Delaying Brain Tumor Progression In Recurrent Disease

Date:
April 14, 2009
Source:
Fred Hutchinson Cancer Research Center
Summary:
The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients.

The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.

Related Articles


The patients all had a recurrent malignant glioma known as alkylator-refractory anaplastic oligodendroglioma (AO), for which there is no existing standard therapy. Oligodendrogliomas begin in brain cells called oligodendrocytes, which provide support around nerves by building a sheath of myelin and facilitating electrical nerve impulses. The relatively uncommon tumor affects about 2,000 persons annually in the U.S. Most are under age 50.

Avastin, known generically as bevacizumab, is the first approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. It is approved so far to treat certain metastatic colon cancers and non-small cell lung cancer.

"Bevacizumab is an important drug for us," said Marc Chamberlain, M.D., author of the study published in the April 15 edition of the journal Cancer. "Of all of the targeted therapies for gliomas, this has been the most promising. And this is practice changing."

Therapy for treating recurrent high-grade gliomas is palliative. All patients with these high-grade tumors eventually die of their cancer. However, bevacizumab has the potential to be the best palliative treatment, according to Chamberlain, who is director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University of Washington School of Medicine.

Chamberlain said he expects that patients treated with the drug will have a marked improvement in their quality of life because the use of steroids, a common treatment that has significant side effects, can be greatly reduced or even eliminated.

"While treatment with Avastin does dramatically improve survival time, the time that patients have left is of better quality and less about living with the disease itself," Chamberlain said. In this study, the patients, ages 24-60, received an infusion of bevacizumab every two weeks for an average of 14.5 cycles (range was two to 39 cycles). Fourteen (64 percent) patients showed a partial response to the medicine as shown on radiographic scans. Two patients had stable disease and six had progressive disease. Progression-free survival ranged from three to 18 months and survival for the entire group of patients was three to 19 months.


Story Source:

The above story is based on materials provided by Fred Hutchinson Cancer Research Center. Note: Materials may be edited for content and length.


Cite This Page:

Fred Hutchinson Cancer Research Center. "Avastin Effective At Delaying Brain Tumor Progression In Recurrent Disease." ScienceDaily. ScienceDaily, 14 April 2009. <www.sciencedaily.com/releases/2009/04/090406151551.htm>.
Fred Hutchinson Cancer Research Center. (2009, April 14). Avastin Effective At Delaying Brain Tumor Progression In Recurrent Disease. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2009/04/090406151551.htm
Fred Hutchinson Cancer Research Center. "Avastin Effective At Delaying Brain Tumor Progression In Recurrent Disease." ScienceDaily. www.sciencedaily.com/releases/2009/04/090406151551.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins